Drug Pricing Activity At US FDA May Be Unique To Gottlieb Tenure
Executive Summary
Steven Grossman argues that the former commissioner possessed the credentials to be out front on the pricing issue, unlike other recent FDA commissioners and the current holder of the office.
You may also be interested in...
Generic Drugs: ‘Competitive’ Exclusivity Benefited Few Sponsors But Is Increasingly Popular
The six months of additional exclusivity from US FDA’s CGT program appears to have kept some generic sponsors from the market, and didn’t even prompt others to enter quickly, but use of the competitive generic exclusivity program continues to grow.
Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals
ANDA approval rates have remained steady, while submission rates dropped compared to prior years.
Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals
ANDA approval rates have remained steady, while submission rates dropped compared to prior years.